Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026838 (
spasticity
)
6,471
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Spasticity
, one of the most frequent comorbidities of spinal cord injury (SCI), disrupts motor recovery and quality of life. Despite major progress in neurorehabilitative and pharmacological approaches, therapeutic strategies for treating
spasticity
are lacking. Here, we show in a mouse model of chronic SCI that treatment with nimodipine-an
L-type calcium channel
blocker already approved from the European Medicine Agency and from the U.S. Food and Drug Administration-starting in the acute phase of SCI completely prevents the development of
spasticity
measured as increased muscle tone and spontaneous spasms. The aberrant muscle activities associated with
spasticity
remain inhibited even after termination of the treatment. Constitutive and conditional silencing of the
L-type calcium channel
Ca
V
1.3 in neuronal subtypes demonstrated that this channel mediated the preventive effect of nimodipine on
spasticity
after SCI. This study identifies a treatment protocol and suggests that targeting Ca
V
1.3 could prevent
spasticity
after SCI.
...
PMID:Early delivery and prolonged treatment with nimodipine prevents the development of spasticity after spinal cord injury in mice. 3229 97
